Opinion

Video

Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials

Panelists discuss emerging data from ongoing trials evaluating innovative combination strategies for endometrial cancer, including insights from the LEAP trial (pembrolizumab + lenvatinib) and the KEYNOTE-B21 trial (pembrolizumab + chemotherapy with or without radiotherapy). They also address treatment considerations for patients with sentinel lymph node–positive disease.

Video content above is prompted by the following:

  1. Briefly comment on other emerging data from ongoing trials evaluating other combination strategies in this setting.
  • LEAP (pembrolizumab + lenvatinib)
  • KEYNOTE-B21 (pembrolizumab + CT±RT)
  • Spoke on sentinel lymph node–positive treatment
Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.